Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Go back to Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial| (AMEX: ACHFF) | Delayed: 0.69 +0.11 (18.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.58 | 52 Week High | $ | |||
| Open | $0.62 | 52 Week Low | $ | |||
| Day High | $0.75 | P/E | N/A | |||
| Day Low | $0.60 | EPS | $ | |||
| Volume | 136,000 | |||||
| (NYSE: ARCH) | Delayed: 134.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $134.83 | 52 Week High | $86.47 | |||
| Open | $134.83 | 52 Week Low | $59.05 | |||
| Day High | $134.83 | P/E | N/A | |||
| Day Low | $134.83 | EPS | $0.00 | |||
| Volume | 28,300 | |||||
